Saturday, July 11, 2026

Drug profile · INN

rimantadine hydrochloride

rimantadine hydrochloride (RIMANTADINE HYDROCHLORIDE) is a influenza virus a matrix protein m2 inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — rimantadine hydrochloride
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

rimantadine hydrochloride (RIMANTADINE HYDROCHLORIDE) is a influenza virus a matrix protein m2 inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN rimantadine hydrochloride
Brand RIMANTADINE HYDROCHLORIDE
Mechanism Influenza virus A matrix protein M2 inhibitor
Target Matrix protein 2
Route ORAL
Formulation SYRUP

Mechanism of action

Influenza virus A matrix protein M2 inhibitor

Primary target: Matrix protein 2

Approval history

Authority Status Date
FDA approved

Frequently asked questions

What is rimantadine hydrochloride?

rimantadine hydrochloride (RIMANTADINE HYDROCHLORIDE) is a influenza virus a matrix protein m2 inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for rimantadine hydrochloride?

RIMANTADINE HYDROCHLORIDE is a marketed brand name for rimantadine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of rimantadine hydrochloride?

rimantadine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.